These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 35022193)

  • 41. Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III-IVA esophageal squamous cell carcinoma post-surgery.
    Li C; Yu P; Li H; Yang X; Wang J; Jiang B
    J Cardiothorac Surg; 2024 Jan; 19(1):26. PubMed ID: 38273405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial.
    Chen X; Xu X; Wang D; Liu J; Sun J; Lu M; Wang R; Hui B; Li X; Zhou C; Wang M; Qiu T; Cui S; Sun N; Li Y; Wang F; Liu C; Shao Y; Luo J; Gu Y
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
    Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
    Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study.
    Yin GQ; Li ZL; Li D
    Cancer Manag Res; 2022; 14():2133-2141. PubMed ID: 35795828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
    Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
    Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis.
    Xiao W; Yuan Y; Wang S; Liao Z; Cai P; Chen B; Zhang R; Wang F; Zeng Z; Gao Y
    Front Immunol; 2021; 12():798451. PubMed ID: 35095878
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center.
    Zhu J; Zhang Y; Wang M; Zhang Z; Yue D; Liu S; Pan Y; Wang C
    Med Sci Monit; 2021 Aug; 27():e930738. PubMed ID: 34376631
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma.
    Fan Y; Jiang Y; Zhou X; Chen Q; Huang Z; Xu Y; Gong L; Yu H; Yang H; Liu J; Lei T; Zhao Q; Mao W
    Oncotarget; 2016 Aug; 7(31):50624-50634. PubMed ID: 27244882
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol.
    Chen M; Huang Y; Zhang S; Zeng T; Huang G; Chen C; Zheng B
    Trials; 2023 Aug; 24(1):554. PubMed ID: 37626367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma.
    Wu C; Zhang G; Wang L; Hu J; Ju Z; Tao H; Li Q; Li J; Zhang W; Sheng J; Hou X; Hu Y
    Oncogene; 2024 Sep; 43(37):2751-2767. PubMed ID: 39122893
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
    Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE).
    Chen Y; Ren M; Li B; Meng Y; Wang C; Jiang P; Song T; Yang J; Zhu D; Yu Q
    J Thorac Dis; 2023 Dec; 15(12):6761-6775. PubMed ID: 38249875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung.
    Feng Y; Sun W; Zhang J; Wang Y; Chen J; Liu X; Wang L; Li S; Lv C; Lu F; Zhang J; Hong Y; Xiao S; Wang T; Jiao R; Wang Z; Qi L; Li N; Yang Y; Lin D; Fang J
    Thorac Cancer; 2022 Feb; 13(3):442-452. PubMed ID: 34913597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design.
    Zheng Y; Li C; Yu B; Zhao S; Li J; Chen X; Li H
    JTCVS Open; 2022 Mar; 9():293-299. PubMed ID: 36003437
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
    He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
    Front Immunol; 2022; 13():853922. PubMed ID: 35720312
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial).
    Yin J; Lin S; Fang Y; Jiao H; Chen Z; Tang H; Gu J; Zhang S; Sun L; Li Y; Han Y; Chen Q; Chen H; Li Z; Tan L
    J Thorac Dis; 2023 Feb; 15(2):718-730. PubMed ID: 36910109
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial.
    Jiang N; Zhang J; Guo Z; Wu Y; Zhao L; Kong C; Song X; Gu L; Zhao Y; Li S; He X; Ren B; Zhu X; Jiang M
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38199609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma.
    Chen F; Qiu L; Mu Y; Sun S; Yuan Y; Shang P; Ji B; Wang Q
    Front Surg; 2022; 9():893372. PubMed ID: 35983558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial.
    Shang X; Xie Y; Yu J; Zhang C; Zhao G; Liang F; Liu L; Zhang W; Li R; Yu W; Yue J; Chen C; Duan X; Ma Z; Chen Z; Xiong Y; Yang F; Xiao J; Zhang R; Liu P; Cheng Y; Cao F; Guo F; Liu G; Meng B; Zhou D; Sun Y; Ren X; Yu J; Hao J; Jiang H
    Cancer Cell; 2024 Oct; 42(10):1747-1763.e7. PubMed ID: 39406186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.